Form D · Biotechnology
Cytex Therapeutics, Inc.
Durham, NC · CIK 0001943908
Offering snapshot reported Jan 10, 2025 · SEC filing
- Reported sold
- $125K Offering amount: $2M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Nov 27, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 10, 2025 | Initial | $125,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-534704
Source: Form D, filed Jan 10, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bradley T Estes | Director, Executive |
| Christine Estes | Executive |
| Farshid Guilak | Director, Executive |
| Franklin T Moutos | Executive |
| David Nolan | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2609 N. Duke Street Suite 303 A
Durham, NC, 27704
Durham, NC, 27704